Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click here to read the full commentary.

Bimagrumab, a drug originally developed for muscle loss, may help reduce the risk of osteoporosis in weight loss medication ...

Noncardiac conditions, such as a blood clot in the lung or hyperthyroidism, may also cause atrial fibrillation. What is the drug of choice for atrial fibrillation? There is no single drug of choice ...

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.